nov1601
Small moleculeexperimental
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 25, 2019 (NCT04014257)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
NTRK2 inhibitor
- Nerve growth factor receptor Trk-AINHIBITOR
NTRK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04014257 | Phase 1 | Jul 25, 2019 | Cha Medical University, CMG Pharmaceutical Co. Ltd, Handok Pharmaceuticals Co., Ltd., National OncoVenture, Seoul National University, The National Cancer Center, Yonsei University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cha Medical University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| CMG Pharmaceutical Co. Ltd | For profit | 1 | 0 | 1 | 2019 |
| Handok Pharmaceuticals Co., Ltd. | For profit | 1 | 0 | 1 | 2019 |
| National OncoVenture | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| The National Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Yonsei University | Academic/Hospital | 1 | 0 | 1 | 2019 |
7 organizations
Page 1 / 1